{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"2.4"}]}],"title":"Baseline pre Cycle 1: positive for HACAs (n=87,85)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"97.6"}]}],"title":"Baseline pre Cycle 1: negative for HACAs (n=87,85)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0"},{"groupId":"OG001","value":"12.0"}]}],"title":"Post-Baseline: positive for HACAs (n=89,85)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.0"},{"groupId":"OG001","value":"88.0"}]}],"title":"Post-Baseline: negative for HACAs (n=89,85)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"85"}],"units":"Participants"}],"description":"In Part 2, samples for the HACA assay were collected at each treatment cycle prior to the administration of rituximab and at each follow-up visit until 24 months after the last dose of rituximab.","groups":[{"description":"Participants received the following in 28-day cycles. Cycle 1: IV rituximab 375 mg/m\\^2 on Day 0 Cycles 2-6: IV rituximab 500 mg/m\\^2 on Day 1 Cycles 1-6: IV fludarabine 25 mg/m\\^2 on Days 1-3 (or as an oral dose of 24 mg/m\\^2 on Days 1-5 or 30-40 mg/m\\^2 on Days 1-3), and IV cyclophosphamide 250 mg/m\\^2 on Days 1-3 (or as an oral dose of 150 mg/m\\^2 on Days 1-5 or 200-250 mg/m\\^2 on Days 1-3).","id":"OG000","title":"Part 2 : Rituximab IV 500 mg/m^2"},{"description":"Participants received the following in 28-day cycles. Cycle 1: IV rituximab 375 mg/m\\^2 on Day 0 Cycles 2-6: SC rituximab 1600 mg on Day 1 Cycles 1-6: IV fludarabine 25 mg/m\\^2 on Days 1-3 (or as an oral dose of 24 mg/m\\^2 on Days 1-5 or 30-40 mg/m\\^2 on Days 1-3), and IV cyclophosphamide 250 mg/m\\^2 on Days 1-3 (or as an oral dose of 150 mg/m\\^2 on Days 1-5 or 200-250 mg/m\\^2 on Days 1-3).","id":"OG001","title":"Part 2: Rituximab SC 1600 mg"}],"paramType":"NUMBER","populationDescription":"SAP; n = number of participants analyzed for the specific parameter.","reportingStatus":"POSTED","timeFrame":"Day 0 of Cycle 1 and Day 1 of Cycles 1, 2, 3, 4, 5, and 6 and at each follow-up visit until 24 months after the last dose of rituximab.","title":"Part 2: Percentage of Participants With Anti-Rituximab Antibodies","type":"SECONDARY","unitOfMeasure":"percentage of participants"}